Covit Pharmaceuticals: plan to change the use of funds raised, extend the appointment of the audit firm, and hold a meeting to review on December 31, 2025.

Kexing Pharmaceutical announced that it will convene the third extraordinary shareholders' meeting on December 31, 2025, to discuss two proposals. The first is to use the 109.1522 million yuan raised from the "Drug Production Base Renovation and Expansion Project" and 15.8678 million yuan in income for the "Research and Development Center Upgrade Construction Project," increasing the total fundraising amount to 472.4824 million yuan, with an implementation deadline extended to December 31, 2028. The second proposal is to re-appoint Zheng Tong Accounting Firm as the auditor for the year 2025, with an audit fee of 1.3 million yuan, the same as in 2024.